Explore

Trendline Trendline
Viridian Therapeutics Announces $350 Million Public Offerings

Viridian Therapeutics Announces $350 Million Public Offerings

Viridian Therapeutics Announces $350 Million Public Offerings
Trendline Trendline
Viridian Therapeutics Raises $350 Million Through Convertible Notes and Stock Offerings

Viridian Therapeutics Raises $350 Million Through Convertible Notes and Stock Offerings

Viridian Therapeutics Raises $350 Million Through Convertible Notes and Stock Offerings
Trendline Trendline
Viridian Therapeutics Launches Public Offerings to Raise Funds for Autoimmune and Rare Disease Treatments

Viridian Therapeutics Launches Public Offerings to Raise Funds for Autoimmune and Rare Disease Treatments

Viridian Therapeutics Launches Public Offerings to Raise Funds for Autoimmune and Rare Disease Treatments
Trendline Trendline
Viridian Therapeutics Launches Public Offerings to Fund Research and Development

Viridian Therapeutics Launches Public Offerings to Fund Research and Development

Viridian Therapeutics Launches Public Offerings to Fund Research and Development
Trendline Trendline
Viridian Therapeutics' New Phase 3 Data Boosts Prospects for Thyroid Eye Disease Drug

Viridian Therapeutics' New Phase 3 Data Boosts Prospects for Thyroid Eye Disease Drug

Viridian Therapeutics' New Phase 3 Data Boosts Prospects for Thyroid Eye Disease Drug
Trendline Trendline
NImmune Biopharma Presents Promising Data for IBD Treatment at Digestive Disease Week

NImmune Biopharma Presents Promising Data for IBD Treatment at Digestive Disease Week

NImmune Biopharma Presents Promising Data for IBD Treatment at Digestive Disease Week
Trendline Trendline
Arrowhead Pharmaceuticals Licenses MASH Program to Madrigal Pharmaceuticals

Arrowhead Pharmaceuticals Licenses MASH Program to Madrigal Pharmaceuticals

Arrowhead Pharmaceuticals Licenses MASH Program to Madrigal Pharmaceuticals
Trendline Trendline
Nuvectis Pharma Reports Increased Net Loss in Q1 2026

Nuvectis Pharma Reports Increased Net Loss in Q1 2026

Nuvectis Pharma Reports Increased Net Loss in Q1 2026
Trendline Trendline
Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept

Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept

Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept
Trendline Trendline
Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion

Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion

Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion
Trendline Trendline
IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026

IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026

IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026
Trendline Trendline
Odyssey Therapeutics Sets Terms for $225 Million IPO Amid Resurgent Biotech Market

Odyssey Therapeutics Sets Terms for $225 Million IPO Amid Resurgent Biotech Market

Odyssey Therapeutics Sets Terms for $225 Million IPO Amid Resurgent Biotech Market